Oncology

Genmab files NDA for large B-cell lymphoma treatment in Japan

Genmab has filed a Japan new drug application (JNDA) with the Ministry of Health, Labor and Welfare (MHLW) of the country for subcutaneous epcoritamab (DuoBody-CD3xCD20) to treat relapsed/refractory (R/R) large B-cell lymphoma (LBCL) patients.

Kite signs agreement to acquire biotech company Tmunity Therapeutics

Gilead Company Kite has signed an agreement to acquire clinical-stage biotech company Tmunity Therapeutics, which is focused on next-generation CAR T-therapies and technologies, for an undisclosed sum.

Moleculin receives Fast Track designation for Glioblastoma Multiforme therapy

Moleculin Biotech has received Fast Track designation from the US Food and Drug Administration (FDA) for WP1122 to treat Glioblastoma Multiforme (GBM), an aggressive malignant primary brain tumour.

Caris and Hummingbird Bioscience collaborate to advance anti-HER3 therapy

Molecular science and technology company Caris Life Sciences (Caris) and data-driven precision biotherapeutics company Hummingbird Bioscience has announced a strategic collaboration to advance clinical development of latter’s anti-HER3 therapy, HMBD-001.

InnoCare receives approval in Singapore for mantle cell lymphoma therapy

InnoCare Pharma has received approval from the Health Sciences Authority (HSA) of Singapore for HIBRUKA (orelabrutinib) to treat adult relapsed or refractory mantle cell lymphoma (R/R MCL) patients.

CG Oncology raises $120m through Series E round

CG Oncology, an oncolytic immunotherapy company, has raised $120m through Series E financing round to advance its lead clinical programmes in bladder cancer towards FDA approval.

Immunomic Therapeutics receives FTD for ITI-3000 programme to treat Merkel Cell Carcinoma

A clinical stage biotechnology company Immunomic Therapeutics has received Fast Track Designation (FTD) from the US Food and Drug Administration (FDA) for its ITI-3000 programme to treat patients with Merkel Cell Carcinoma (MCC).

Kite, Refuge sign license deal for gene expression platform for blood cancers

Kite, a Gilead Company, has signed a global license agreement with Refuge Biotechnologies, a synthetic biology company for cancer immunotherapy, for exclusive rights to use latter’s gene expression platform to develop potential treatments for blood cancers.

Gilead’s Kite gets EC approval for Yescarta to treat DLBCL and HGBL

Gilead Sciences company Kite has secured approval from the European Commission (EC) for Yescarta (axicabtagene ciloleucel) to treat adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL).